UC Santa Cruz chemist argues P3 peptide drives Alzheimer's pathology

The wire

1. 01A commentary in ChemBioChem from UC Santa Cruz biochemist Jevgenij Raskatov argues P3, an alpha-secretase product long considered harmless, forms clumps and fibrils, sometimes faster than amyloid beta.
2. 02More than 400 clinical trials have targeted amyloid beta with limited benefit; a second aggregating peptide would widen the target list beyond lecanemab- and donanemab-style antibodies.
3. 03This is a commentary rather than new clinical data, and Raskatov himself says more research is needed before P3 is established as neurotoxic in humans.

From the source

New Research Suggests Overlooked Peptide P3 May Contribute to Alzheimer’s Disease

For decades, the focus of Alzheimer’s research has revolved around targeting amyloid beta, a peptide known to accumulate in harmful deposits in the brain. However, a new perspective is emerging from the University of California, Santa Cruz, where biochemist Jevgenij Raskatov suggests that another peptide, previously dismissed as harmless, could play a significant role in the disease’s development.